📊 RVPH Key Takeaways
Is Reviva Pharmaceuticals Holdings, Inc.. (RVPH) a Good Investment?
Reviva is a pre-revenue/minimal-revenue stage pharmaceutical company with unsustainable cash burn of $3.8M per quarter against only $122.9K in revenue, resulting in -2601% net margins. Despite a strong absolute cash position of $22.2M and zero debt, the company is consuming capital rapidly and has approximately 1.5 years of runway at current burn rates. Positive 81.5% YoY revenue growth is meaningless from near-zero baseline and does not demonstrate clear commercialization or product-market viability.
Reviva Pharmaceuticals Holdings, Inc.. Key Strengths (RVPH)
- Strong cash position of $22.2M with no debt provides operational flexibility and eliminates refinancing risk in near term
- Excellent liquidity ratios (3.85x current/quick) indicate no immediate solvency concerns
- Revenue growing 81.5% YoY suggests early product traction or market entry, though from negligible base
RVPH Stock Risks: Reviva Pharmaceuticals Holdings, Inc.. Investment Risks
- Unsustainable cash burn of $3.8M per period against minimal revenue creates 18-month funding runway at current rates
- Extreme operating losses (-2663% margin) with no visible path to profitability indicate fundamental business model challenges or pre-commercialization stage with execution risk
- Minimal revenue generation ($122.9K) reveals severe commercialization failures, product rejection, or lack of market demand; survival depends entirely on securing additional capital or dramatic revenue acceleration
Key Metrics to Watch
- Quarterly operating cash burn rate and remaining cash runway duration
- Revenue growth trajectory and gross margin achievement once revenue scales meaningfully
- Pipeline progress and FDA approval status of candidate drugs to assess probability of future revenue sustainability
Reviva Pharmaceuticals Holdings, Inc.. (RVPH) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.85x current ratio provides a solid financial cushion.
RVPH Profit Margin, ROE & Profitability Analysis
RVPH vs Healthcare Sector: How Reviva Pharmaceuticals Holdings, Inc.. Compares
How Reviva Pharmaceuticals Holdings, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Reviva Pharmaceuticals Holdings, Inc.. Stock Overvalued? RVPH Valuation Analysis 2026
Based on fundamental analysis, Reviva Pharmaceuticals Holdings, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Reviva Pharmaceuticals Holdings, Inc.. Balance Sheet: RVPH Debt, Cash & Liquidity
RVPH Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Reviva Pharmaceuticals Holdings, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-17.73 indicates the company is currently unprofitable.
RVPH Revenue Growth, EPS Growth & YoY Performance
Reviva Pharmaceuticals Holdings, Inc.. Dividends, Buybacks & Capital Allocation
RVPH SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Reviva Pharmaceuticals Holdings, Inc.. (CIK: 0001742927)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RVPH
What is the AI rating for RVPH?
Reviva Pharmaceuticals Holdings, Inc.. (RVPH) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RVPH's key strengths?
Claude: Strong cash position of $22.2M with no debt provides operational flexibility and eliminates refinancing risk in near term. Excellent liquidity ratios (3.85x current/quick) indicate no immediate solvency concerns.
What are the risks of investing in RVPH?
Claude: Unsustainable cash burn of $3.8M per period against minimal revenue creates 18-month funding runway at current rates. Extreme operating losses (-2663% margin) with no visible path to profitability indicate fundamental business model challenges or pre-commercialization stage with execution risk.
What is RVPH's revenue and growth?
Reviva Pharmaceuticals Holdings, Inc.. reported revenue of $122.9K.
Does RVPH pay dividends?
Reviva Pharmaceuticals Holdings, Inc.. does not currently pay dividends.
Where can I find RVPH SEC filings?
Official SEC filings for Reviva Pharmaceuticals Holdings, Inc.. (CIK: 0001742927) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RVPH's EPS?
Reviva Pharmaceuticals Holdings, Inc.. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RVPH's fundamental grade?
Based on our AI fundamental analysis in May 2026, Reviva Pharmaceuticals Holdings, Inc.. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RVPH stock overvalued or undervalued?
Valuation metrics for RVPH: ROE of -18.3% (sector avg: 15%), net margin of -2,601.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RVPH's AI grade for 2026?
Our dual AI analysis gives Reviva Pharmaceuticals Holdings, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RVPH's free cash flow?
Reviva Pharmaceuticals Holdings, Inc..'s operating cash flow is $-3.8M, with capital expenditures of N/A. FCF margin is -3,093.8%.
How does RVPH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,601.2% (avg: 12%), ROE -18.3% (avg: 15%), current ratio 3.85 (avg: 2).